The combined global market size of medical conditions we target exceeds US$400B per annum. This potential addressable market is calculated by combining the treatment markets of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and generalised anxiety disorder (GAD). Success in the clinical development programmes will not only provide benefit to patients, but also offer significant economic potential for our shareholders.
IHL – 42X – OSA IHL-42X is a novel cannabinoid combination product for treatment of Obstructive Sleep Apnoea (OSA).
US$400B market potential.
Latest results and presentations
Stay up to date with Incannex’s research and development program.